1. Hyaluronan concentration and molecular mass in psoriatic arthritis: biomarkers of disease severity, resistance to treatment, and outcome
- Author
-
Anders Larsson, Urban Hellman, Anna Engström-Laurent, and Ulla Lindqvist
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Immunology ,Drug Resistance ,Arthritis ,Severity of Illness Index ,Chemistry Techniques, Analytical ,03 medical and health sciences ,Psoriatic arthritis ,0302 clinical medicine ,Rheumatology ,Disease severity ,Internal medicine ,Severity of illness ,medicine ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,Hyaluronic Acid ,Treatment resistance ,Correlation of Data ,Skin ,Rheumatology and Autoimmunity ,030203 arthritis & rheumatology ,Reumatologi och inflammation ,integumentary system ,Molecular mass ,Tumor Necrosis Factor-alpha ,business.industry ,Arthritis, Psoriatic ,Adalimumab ,Patient Acuity ,food and beverages ,General Medicine ,Middle Aged ,medicine.disease ,Treatment Outcome ,Cytokine ,Antirheumatic Agents ,Female ,business ,Biomarkers - Abstract
Objective: Low molecular mass hyaluronan causes inflammatory processes and can act as a pro-inflammatory cytokine in skin and other sites of activity in psoriatic arthritis (PsA). This study investigated whether the molecular mass distribution of hyaluronan (HA) in skin and the quantity of circulating HA are related to the clinical inflammatory picture in PsA with active disease and to the effect of treatment with anti-tumour necrosis factor-α (anti-TNF-α) adalimumab. Methods: Twenty patients with TNF-α-naïve active polyarticular PsA were included in this prospective clinical trial of treatment with 40 mg s.c. adalimumab according to standard procedure. Clinical activity, patients’ assessments, and skin biopsies were captured at inclusion and at the 12 week follow-up. Ten healthy individuals were recruited for comparison of HA analyses. Histochemistry of skin inflammation, serum HA, and molecular mass of HA were determined. Results: Overall improvements in clinical parameters were observed. Eight of 18 patients reached minimum disease activity after 12 weeks and disease activity was significantly reduced (p
- Published
- 2019
- Full Text
- View/download PDF